Literature DB >> 9499449

Glutathione-related mechanisms in cellular resistance to anticancer drugs.

K Zhang1, P Mack, K P Wong.   

Abstract

Glutathione conjugation and transport of glutathione conjugates of anticancer drugs out of cells have been shown to work as a system in the detoxification of many anticancer drugs. The major components of this system include glutathione (GSH), GSH-related enzymes and glutathione conjugate export pump (GS-X pump). GSH can combine with anticancer drugs to form less toxic and more water soluble GSH conjugates, the conjugation reaction is catalysed by glutathione S-transferases (GSTs). The GSH conjugates of anticancer drugs can be exported from cells by GS-X pump or multidrug resistance-associated protein (MRP). GSH, glutathione-related enzymes and GS-X pump or MRP have been found to be increased or overexpressed in many drug resistant cells. Increased detoxification of anticancer drugs by this system may confer drug resistance. Inhibition of this detoxification system is a strategy for modulation of drug resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499449     DOI: 10.3892/ijo.12.4.871

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  26 in total

1.  Antioxidant enzymes in blood of patients with Friedreich's ataxia.

Authors:  G Tozzi; M Nuccetelli; M Lo Bello; S Bernardini; L Bellincampi; S Ballerini; L M Gaeta; C Casali; A Pastore; G Federici; E Bertini; F Piemonte
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

2.  Overexpression of the regulatory subunit of gamma-glutamylcysteine synthetase in HeLa cells increases gamma-glutamylcysteine synthetase activity and confers drug resistance.

Authors:  S R Tipnis; D G Blake; A G Shepherd; L I McLellan
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

3.  Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival.

Authors:  Sally Järvelä; Järvelä Sally; Helena Bragge; Bragge Helena; Niina Paunu; Paunu Niina; Timo Järvelä; Järvelä Timo; Leo Paljärvi; Paljärvi Leo; Hannu Kalimo; Kalimo Hannu; Pauli Helén; Helén Pauli; Vuokko Kinnula; Kinnula Vuokko; Ylermi Soini; Soini Ylermi; Hannu Haapasalo; Haapasalo Hannu
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

4.  Lack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy.

Authors:  Mojgan Mirakhorli; Nasrin Shayanfar; Sabariah Abdul Rahman; Rozita Rosli; Syahrilnizam Abdullah; Ahad Khoshzaban
Journal:  Oncol Lett       Date:  2012-08-31       Impact factor: 2.967

5.  Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Authors:  Daniel J Guillaume; Nancy D Doolittle; Seymur Gahramanov; Nancy A Hedrick; Johnny B Delashaw; Edward A Neuwelt
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

6.  miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2.

Authors:  Wei Zhu; DanXia Zhu; Shiqiang Lu; Tongshan Wang; Jian Wang; Binghua Jiang; Yongqian Shu; Ping Liu
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

7.  Chronic low vitamin intake potentiates cisplatin-induced intestinal epithelial cell apoptosis in WNIN rats.

Authors:  Bodiga Vijayalakshmi; Boindala Sesikeran; Putcha Udaykumar; Subramaniam Kalyanasundaram; Manchala Raghunath
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

8.  Decreased expression of antioxidant enzymes is associated with aggressive features in ependymomas.

Authors:  Sally Järvelä; Kristiina Nordfors; Miia Jansson; Joonas Haapasalo; Pauli Helén; Leo Paljärvi; Hannu Kalimo; Vuokko Kinnula; Ylermi Soini; Hannu Haapasalo
Journal:  J Neurooncol       Date:  2008-08-06       Impact factor: 4.130

9.  Predictive and prognostic markers in colorectal cancer.

Authors:  Peter M Wilson; Robert D Ladner; Heinz-Josef Lenz
Journal:  Gastrointest Cancer Res       Date:  2007-11

Review 10.  A new view of carcinogenesis and an alternative approach to cancer therapy.

Authors:  Miguel López-Lázaro
Journal:  Mol Med       Date:  2009-12-28       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.